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Blood transfusion during heparin-free hemodialysis
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The routine practice of hemodialysis requires anticoagulation
to prevent thrombosis in the extracorporeal circuit [1, 2]. Heparin
is used as the anticoagulant in the vast majority of treatments. In
patients at risk of bleeding, techniques to avoid anticoagulation
have been developed. These techniques include heparin free
protocols using rapid blood flow and saline flushes [3—7], and
various techniques for regional anticoagulation including citrate
and prostacyclin regional anticoagulation [8—151.
We and others have described techniques for heparin-free
hemodialysis [3—7]. In our 1989 study, we were successful in
hemodialyzing 91% of hospitalized patients with significant bleed-
ing risks without the use of anticoagulants. Less than 2% of these
patients thrombosed their hemodialysis circuit and only 7%
required very low dose (< 1000 i.r) heparin during this protocol.
However, we and others noted that blood transfusion through the
hemodialysis Circuit dramatically increased the likelihood of ex-
tracorporeal thrombosis [1—3]. Thus, protocols for heparin-free
hemodialysis requiring fast blood flows and saline flushes have
prohibited transfusion during the dialysis treatment through the
dialysis circuit [1—3]. Given that large numbers of acutely bleeding
patients require blood transfusions, we have worked to develop a
technique to modify our heparin-free hemodialysis protocol so
transfusions can be safely performed via the hemodialysis circuit
without compromising the hemodialysis treatment. In addition,
intravenous accesses are often a limiting factor in acutely ill
patients and the ability to transfuse through the dialysis circuit
while providing simultaneous ultrafiltration improves patient care.
This study describes our experience with a modification of our
heparin-free hemodialysis protocol that allows transfusion
through the hemodialysis circuit.
Methods
Twenty-seven consecutive inpatients, who required transfusion
while requiring heparin-frec hemodialysis, were studied during
the period of January through September 1996. The demograph-
ics of the patient population is described in Table 1. No patient
who required transfusion and heparin free hemodialysis was
excluded from this protocol. All patients were in the high or very
high risk of bleeding group using the classification devised by
Swartz and Port [16]. The location where the patient received the
therapy (in the intensive care unit or in the acute hemodialysis
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unit), the artificial kidney employed, and the access used, are
described in Table 1.
All patients received blood transfusions while dialyzed without
heparin. Hemodialysis without anticoagulation was performed
using the standard protocol as described at our center in 1987 [3].
Briefly, the protocol required that the artificial kidney and blood
line be flushed for 10 to 15 minutes with one liter of 0.9% saline
containing 3000 units of heparin. Heparin was then flushed from
the dialyzer and the blood lines with at least one liter of 0.9%
saline solution before blood flow was initiated. In this manner
heparin was always displaced prior to the initiation of hemodial-
ysis. Commonly used measures of anticoagulation in the extracor-
poreal and systemic circulation [prothrombin time (PT) and
(activated thromboplastin time (PIT)] did not change pre-,
during, or post-hemodialysis [3]. Blood flows of more than 250
mI/mm were established rapidly and maintained at this level.
When possible, blood flows were kept between 300 and 350
ml/min. Systolic blood pressure was maintained at> 100 mm Hg
by the use of fluid replacement or vasopressors, as clinically
indicated. Venous and arterial pressure monitors were used in all
instances and were carefully monitored to detect extracorporeal
thrombosis. The artificial kidney was flushed with 50 ml of 0.9%
saline every 15 to 30 minutes to detect any signs of partial clotting
and to prevent hemoconcentration. Partial clotting could usually
be detected by either increments in the venous pressure or
decreases in the arterial pressure monitor readings, or by the
detection of fibrin stranding either in the kidney or in the blood
drip chambers. If partial clotting could not be resolved with saline
flushes, the patient received a low dose heparin regimen. This
method involved administering 500 units of heparin systemically
every 15 to 30 minutes with a maximum of 1,500 units per
treatment. One-to-one or one-to-two nursing was characteristi-
cally used in conjunction with this technique.
Patients were assigned to receive blood transfusion during
hemodialysis on the sole basis of having indication for transfusion
and having a high or very high risk for bleeding using the
classification system of Swartz and Port [16]. The attending
nephrologist and the managing physician determined the require-
ment for transfusion and heparin free hemodialysis. The study
team was not involved in the decision as to whether transfusion or
heparin free hemodialysis was required. The time required per
transfusion of packed red blood cells was 30 to 60 minutes of
dialysis time. The only modification to the standard dialysis
treatment was the introduction of a sterile three-way stopcock
into the blood flow path (Fig. 1). This sterile stopcock was placed
between the distal extreme of the dialysis venous circuit tubing
and the standard extension tubing from the access needle or the
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%
Age
Gender
male 14 52
female 13 48
Location
ICU 20 50
Acute HD unit 20 50
Access
DialysisCath. (non-cuffed) 19 47.5
Permcath (cuffed cath) 12 30
PTFE 6 15
Tesio Cath r (cuffed cath) 1 2.5
AVF 2 5
Filters
HGSOO 27 67.5
A500 8 20
HG400 2 5
A700 2 5
F20 1 2.5
Indication for no heparin
Recent surgery 19
Recent bleeding 10
Suspected aneurysm 2
Other 9
hemodialysis catheter (Figs. 1 and 2). Access needles were 15
gauge in all instances of AV access. Hemodialysis catheters used
are described in Table 1.
A stopcock with large diameter channels and Luer locks was
used to facilitate blood flow and to prevent any unsuspected
detachment in this circuitry (Figs. 1 and 2). The proper position-
ing and attachments are depicted in Figure 1. The operator had to
be certain that the device flowed in three ways simultaneously by
twisting the lock valve 180 degrees away from the side port
position (Fig. 1). In this manner the blood ran in a straight line
through the stopcock and the blood infusion was able to come
from the side port (Figs. I and 2). The arrows present on the
stopcock guided the operator regarding flow direction (Figs. 1 and
2). The arrows must be perfectly aligned with the circuitry access
to guarantee the path of minimal resistance to the bloodstream.
Once the device had been safely placed, the dialysis was com-
menced and ran on a standard basis. Venous and arterial dialysis
pressures were followed carefully from the extracorporeal circuit.
Baseline pressures at 300 ml/min were compared with those while
transfusing at 300 mI/mm. An increase in venous pressure was
expected due to the blood infusing under pressure in the positive
pressure venous side. If a substantial (> 80 mm Hg) increase in
venous pressure was encountered, the venous access circuit was
analyzed for errors in stopcock placement and arrow alignment,
catheter kink or clotting in the hemodialysis circuit or problems
with venous inflow.
The transfusion circuitry was the standard transfusion equip-
ment that connected to the described stopcock (Figs. 1 and 2). In
order to facilitate transfusion, one of two maneuvers may be
required to transfuse into this high pressure venous circuit: (1)
The blood transfusion bag could be placed one meter above the
patient to develop sufficient pressure gradient to enter this inflow
circuit; or (2) A pressure bag could be attached to the transfusing
blood unit and increased up to 300 mm Hg as necessary to
facilitate blood entry. The transfusion line was locked at the end
of each transfusion by rotating the stopcock handle to close the flow
from the transfusion circuit to prevent retrograde flow. If retrograde
flow occurred during transfusion with the blood elevated 1 meter
above the patient the stopcock was closed and the pressure bag
applied. Twenty milliliters or less of blood were expected to remain
in the transfusion circuit. It is essential that the transfusion bag not be
vented, as it is possible that air may enter the system.
All hemodialysis was performed using a CUBE Centry3 hemo-
dialysis machine. Artificial kidneys (Filters) were either he-
mophane 0.9 to 1.1 meter squared hollow fiber (HG 400, 500), or
a cuprophane parallel plate 1.1 and 1.3 square meter, (Alpha 500
or 700) or an AN69 2.0 meter2 hollow fiber (Filtral 20, F-20); all
of these from Cobe Renal Care (Lakewood, CU, USA; Table 1).
Hemodialysis frequency was three to five times per week for an
average of three to four hours per session. A bicarbonate bath
with a sodium concentration varying between 140 to 148 was used
with dialysate flows of 600 mI/mm and blood flows between 250
and 400 ml/min.
Results
Twenty-seven consecutive inpatients, requiring transfusion dur-
ing 40 heparin-free hemodialysis, were entered into this study
between January and September 1996. All sessions were carried
out in intensive care units or the acute dialysis unit at DUMC
(Table 1). Eleven patients were transfused more than once. Eighty
units of packed red blood cells were transfused. Each patient
received from I to 3 units, with an average of 2 units per dialysis
session. The mean blood flow and the mean duration of hemodi-
alysis were 300 mI/mm and three hours, respectively. All patients
who needed transfusions of blood during heparin free hemodial-
ysis were included (Table 2).
The standard protocol for no heparin dialysis was followed
without any alterations except for the inclusion of the described
stopcock at the venous outflow port. Of the 40 consecutive
treatments, all 40 were completed without conversion to low dose
heparin. There were no clotting episodes of the extracorporeal
circuit, and no treatments were terminated early. Patient coagu-
lation parameters defined by prothrombin time (PT) and acti-
vated partial thromboplastin time (AP1T) were normal prior to
and after 36 of 40 treatments. Four treatments were performed in
patients with a coagulopathy as defined by PT and APTT elevated
pre-treatment. Venous outflow pressure increased above the
pre-transfusion baseline by a mean of 30 mm Hg (Table 2). This
elevation in venous outflow pressure characteristically returned to
baseline when the transfusion was completed. Thirty-two treat-
ments were delivered via a temporary hemodialysis catheter,
either in the internal jugular, or the femoral position. When
hemodialysis catheters were used a saline pressure bag infusion
system rather than heparin was used to maintain catheter patency.
Eight treatments were done via an arteriovenous access, either by
an AV graft [6] or AV fistula (Table 1) [2].
Discussion
The routine practice of hemodialysis requires systemic antico-
agulation to prevent thrombosis in the extracorporeal blood
circulation [1, 2]. Heparin remains the most commonly used
anticoagulant. Bleeding is a major complication associated with
hemodialysis, especially in hospitalized patients predisposed to
bleed as a result of surgery, trauma, previous bleeding or already
demonstrating active bleeding. Controlled trials evaluating the
Table 1. Patients
Number
55.4 14.5
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Fig. 1. Hemodialysis Circuit schematic showing the three-way stopcock attached to dialysis catheter and blood tubing with luer lock connectors. White arrows
demonstrate the direction of blood flow in the circuit and direction of blood transfusion. The black arrow demonstrates the position of the three-way
stop cock handle to allow blood transfusion and hemodialysis.
j NO HEPARIN TRANSFUSION I
Fig. 2. Transfusion and dialysis circuit showing
direction of transfusion and blood flow.
effectiveness of protamine regional anticoagulation versus low
dose systemic heparinization have been completed [16]. Swartz
and Port demonstrated that low-dose systemic heparin anticoag-
ulation produced fewer bleeding episodes than protamine re-
gional anticoagulation [16]. Nonetheless, significant bleeding
complications were described in their study. Difficulties in the
appropriate dose of protamine and the dissociation of the heparin
protamine complex by the reticuloendothelial system after hemo-
dialysis (rebound bleeding) were the proposed reasons for failure
of protamine regional anticoagulation to be successful [16].
I VP I
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machine
________
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Table 2. Results
Patients 27
Blood
Number of units
Range
Mean PRBC/patient
Venous Dialysis Pressures (VDP)
VDP pre-transfusion
VDP post-transfusion
Mean VDP incr. mm Hg
Range mm Hg
Dialysis
QB mI/mm mean
Range mi/nun
Mean duration hours
Range hours Acknowlegement
% Convert/heparin We acknowledge the participation, skill, and perseverance of the nurses
of the Duke University Acute Dialysis Program, without whose attention
to improvements in patient care this study would not have been possible.
Reprint requests to Steve J. Schwab, M.D., Duke University Medical Center,
Hospital Box 30/4, Durham, North Carolina 27710, USA.
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hemodialysis requires one—to—one or at least one—to—two
nursing, this was not found to be a problem. All 27 patients
successfully completed this transfusion protocol without a need to
80 resort to heparin. No treatments were aborted. Thus, one of the
1—3 principle drawbacks with the heparin free dialysis can be resolved
2 by a simple protocol modification as described here. We are
246 79 unsure why we were more successful with this modification of our
281 51 heparin free protocol as compared with our inintial study [3]. Our
30 current success rate with the original protocol without resorting to
(70)_(+126) heparin is now 95%. Thus, as we continue to use this protocol
300 modification we anticipate a need to use low dose heparin in only
250—400 a small percentage of patients.
3
1.5—4
0%
Alternate agents for regional anticoagulation have included citrate
and prostacyclin [8—15]. Morita and colleagues first described the
technique of regional anticoagulation using citrate [181. Subse-
quent modifications by Pinnick, Wiegmann and Diederich [13],
Von Brecht and colleagues [151, and a prospective trial by
Flannigan and associates [141 showed the utility of citrate regional
anticoagulation. Complications with citrate regional anticoagula-
tion include hypocalcemia, hypercalcemia and citrate toxicity.
Some of these complications were initially described by Kelliher
and Schulman [17]. Regional anticoagulation using prostacyclin
has been reported [17]. Prostacyclin inhibits platelet activation
without affecting the intrinsic clotting system and has a physiologic
half-life of approximately five minutes. Prostacyclin's principle
side effects include its potent vasodilatory properties and associ-
ated nausea and vomiting, and facial flushing. These complica-
tions have limited the application of this technique [12].
Heparin free hemodialysis has emerged as the most common
technique for dialyzing patients at risk of bleeding. Glaser et al
were the first in reporting successful performance of heparin-free
dialysis [71. Investigators at the University of Alabama [4] and
Duke University [31, further modified and developed these tech-
niques for heparin free dialysis. We and others have reported
successful hemodialysis without the use of anticoagulation in >
91% of patients employed while maintaining hemodialysis effi-
ciency. The principle drawback of this technique has been the
inability to transfuse simultaneously through the hemodialysis
circuit. It has been reasoned that the increased clotting seen with
this technique and transfusion has been mediated by hemocon-
centration when blood is transfused through the hemodialysis
circuit. This is a significant drawback of this dialysis technique.
We reasoned that if one could place the blood infusion port
distal enough in the venous circuit and infuse it under pressure,
since the blood was not passing through either the artificial kidney
or the drip chamber, the hemoconcentration would not increase
extracorporeal thrombosis. We also reasoned that if problem
developed with access flow, it would be readily detected by
carefully monitoring the venous outflow pressures.
In this study we have successfully shown that 27 consecutive
patients could be transfused, in 40 independent dialysis sessions,
with this method during the heparin-free hemodialysis protocol
without any significant difficulty. This technique only requires the
addition of a stopcock and additional attention by the nursing staff
to the venous pressure during the transfusion. Since no heparin
